Publications

 

  1. Trosman JR, Weldon CB, Douglas MP, Kurian AW, Kelley RK, Deverka PA, Phillips KA. Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative. J Natl Compr Canc Netw. 2017; Feb;15(2):219-228. https://www.ncbi.nlm.nih.gov/pubmed/28188191
  2. Dervan AP, Deverka PA, Trosman JR, Weldon CB, Douglas MP, and Phillips KA. Payer Decision-Making for Next Generation Sequencing-Based Genetic Tests: Insights from Cell-Free DNA Prenatal Screening. Genet Med. 2017; May;19(5):559-567. https://www.ncbi.nlm.nih.gov/pubmed/27657682
  3. Marshall DA, Gonzalez JM, MacDonald KV, et al. Estimating Preferences for Complex Health Technologies: Lessons Learned and Implications for Personalized Medicine. Value Health. 2017;20(1): 32-39. https://www.ncbi.nlm.nih.gov/pubmed/28212966
  4. Phillips KA, Douglas MP, Trosman JR, et al. "What Goes Around Comes Around": Lessons Learned from Economic Evaluations of Personalized Medicine Applied to Digital Medicine. Value Health. 2017;20(1): 47-53. https://www.ncbi.nlm.nih.gov/pubmed/28212968
  5. Trosman JR, Weldon CB, Douglas MP, et al. Decision-Making on Medical Innovations in a Changing Health Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies. Value Health. 2017;20(1): 40-46. https://www.ncbi.nlm.nih.gov/pubmed/28212967
  6. Marshall DA, MacDonald KV, Oliver Robinson J, Barcellos LF, Gianfrancesco M, Helm M, McGuire A, Green RC, Douglas MP, Goldman MA, Phillips KA. The price of whole genome sequencing may be decreasing, but who will be sequenced? Personalized Medicine. 2017; 14(2): 203-211. https://www.futuremedicine.com/doi/abs/10.2217/pme-2016-0075
  7. Phillips KA, Deverka PA, Sox HC, Khoury MJ, Sandy LG, Ginsburg GS, Tunis SR, Orlando LA, Douglas MP. Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research. Genet Med. 2017; 19:1081-1091. https://www.ncbi.nlm.nih.gov/pubmed/28406488
  8. Phillips KA, Deverka PA, Trosman JR, Douglas MP, Chambers JD, Weldon CB, Dervan AP. Payer coverage policies for multigene tests. Nat Biotechnol. 2017 Jul 12;35(7):614-617. https://www.ncbi.nlm.nih.gov/pubmed/28700544
  9. Marshall DA, Gonzalez JM, Johnson FR, MacDonald KV, Pugh A, Douglas MP, Phillips KA. What are people willing to pay for whole-genome sequencing information, and who decides what they receive? Genet Med. 2016, 18(2):1295-1302. http://www.ncbi.nlm.nih.gov/pubmed/27253734
  10. Phillips KA, Schleifer D, Hagelskamp C. Most Americans Do Not Believe That There Is An Association Between Health Care Prices And Quality Of Care. Health Affairs. 2016, 35:647-653. http://www.ncbi.nlm.nih.gov/pubmed/27044965
  11. Payne K, Redekop K, and Phillips KA. (2016) Personalized Medicine: Economic Evaluation and Evidence (book chapter). In World Scientific Handbook of Global Health Economics and Public Policy, Vol. 2, edited by Richard M. Scheffler. World Scientific, Imperial College Press. Hackensack, NJ.
  12. Phillips KA, Pletcher MJ, Ladabaum U. Is the “$1000 Genome” Really $1000? Understanding the Full Benefits and Costs of Genomic Sequencing. Technol Health Care 2015. 23(3)373-379. http://www.ncbi.nlm.nih.gov/pubmed/25669213
  13. Trosman JR, Weldon CB, Kelley RK, Phillips KA. Challenges of coverage policy development for next-generation tumor sequencing panels: Experts and Payers Weigh in. JNCCN. 2015. 13(3):311-8. http://www.ncbi.nlm.nih.gov/pubmed/25736008
  14. Phillips KA, Ladabaum U, Pletcher MJ, Marshall DA, Douglas MP. Key emerging themes for assessing the cost-effectiveness of reporting incidental findings. Genet Med. 2015. 17(4):314-5. http://www.ncbi.nlm.nih.gov/pubmed/25835195
  15. Douglas MP, Ladabaum U, Pletcher MJ, Marshall DA, Phillips KA. Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping review. Genet Med. 2016. 18(2):111-116. http://www.ncbi.nlm.nih.gov/pubmed/25996638
  16. Clain E, Trosman JR, Douglas MP, Weldon CB, and Phillips KA. Availability and payer coverage of BRCA1/2 tests and gene panels. Nat Biotechnol. 2015. 33(9):900-2. http://www.ncbi.nlm.nih.gov/pubmed/26348951
  17. Garfield, S., M. P. Douglas, K. V. MacDonald, D. A. Marshall and K. A. Phillips (2015). "Consumer familiarity, perspectives and expected value of personalized medicine with a focus on applications in oncology." Personalized Medicine. 12(1): 13-22. http://www.futuremedicine.com/doi/full/10.2217/pme.14.74
  18. Schink, J. C., J. R. Trosman, C. B. Weldon, K. P. Siziopikou, G. J. Tsongalis, A. W. Rademaker, J. D. Patel, A. B. Benson, 3rd, E. A. Perez and W. J. Gradishar (2014). "Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers." J Natl Cancer Inst 106(10). PMCID: 4176043. http://www.ncbi.nlm.nih.gov/pubmed/25217578
  19. Phillips, K. A., J. R. Trosman, R. K. Kelley, M. J. Pletcher, M. P. Douglas and C. B. Weldon (2014). "Genomic sequencing: assessing the health care system, policy, and big-data implications." Health Aff (Millwood) 33(7): 1246-1253. PMCID: 4113721. http://www.ncbi.nlm.nih.gov/pubmed/25006153
  20. Phillips, K. A., J. Ann Sakowski, J. Trosman, M. P. Douglas, S. Y. Liang and P. Neumann (2014). "The economic value of personalized medicine tests: what we know and what we need to know." Genet Med 16(3): 251-257. PMCID: 3949119. http://www.ncbi.nlm.nih.gov/pubmed/24232413
  21. Phillips, K. A. and L. A. (2014). "“SHINING A LIGHT” on Companies Providing Healthcare Price Transparency Data. ." JMCM 17(4): 75-79. http://jmcmpub.org/pdf/17-4/?pdf_page=75
  22. Trosman, J. R., C. B. Weldon, J. C. Schink, W. J. Gradishar and A. B. Benson, 3rd (2013). "What do providers, payers and patients need from comparative effectiveness research on diagnostics? The case of HER2/Neu testing in breast cancer." J Comp Eff Res 2(4): 461-477. http://www.ncbi.nlm.nih.gov/pubmed/24236686
  23. Shin, J., S. Y. Liang, M. J. Hassett, K. A. Phillips and J. S. Haas (2013). "Utilization of cardiac monitoring tests in women with non-metastatic breast cancer treated with trastuzumab." Personalized Medicine 10(7): 703-708. http://www.futuremedicine.com/doi/full/10.2217/pme.13.68
  24. Phillips, K. A., J. S. Sakowski, S. Y. Liang and N. A. Ponce (2013). "Economic Perspectives on Personalized Health Care and Prevention. ." Forum for Health Economics and Policy. 16(2): S23-S52. http://www.degruyter.com/view/j/fhep.2013.16.issue-2/fhep-2013-0010/fhep-2013-0010.xml?rskey=dVaq6A&result=4
  25. Kuppermann, M., G. Wang, S. Wong, A. Blanco, P. Conrad, S. Nakagawa, J. Terdiman and U. Ladabaum (2013). "Preferences for outcomes associated with decisions to undergo or forgo genetic testing for Lynch syndrome." Cancer 119(1): 215-225. http://www.ncbi.nlm.nih.gov/pubmed/22786716
  26. Ferrusi, I. L., C. C. Earle, M. Trudeau, N. B. Leighl, E. Pullenayegum, H. Khong, J. S. Hoch and D. A. Marshall (2013). "Closing the personalized medicine information gap: HER2 test documentation practice." Am J Manag Care 19(1): 838-844. PMCID: 3919466. http://www.ncbi.nlm.nih.gov/pubmed/23379747
  27. Weldon, C. B., J. R. Trosman, W. J. Gradishar, A. B. Benson, 3rd and J. C. Schink (2012). "Barriers to the use of personalized medicine in breast cancer." J Oncol Pract 8(4): e24-31. PMCID: 3396824. http://www.ncbi.nlm.nih.gov/pubmed/23180995
  28. Wang, G., M. Kuppermann, B. Kim, K. A. Phillips and U. Ladabaum (2012). "Influence of patient preferences on the cost-effectiveness of screening for Lynch syndrome." Am J Manag Care 18(5): e179-185. http://www.ncbi.nlm.nih.gov/pubmed/22694112
  29. Wang, G., M. Kuppermann, B. Kim, K. A. Phillips and U. Ladabaum (2012). "Influence of patient preferences on the cost-effectiveness of screening for lynch syndrome." J Oncol Pract 8(3 Suppl): e24s-30s. PMCID: 3348599. http://www.ncbi.nlm.nih.gov/pubmed/22942831
  30. Walsh, J., M. Arora, C. Hosenfeld, U. Ladabaum, M. Kuppermann and S. J. Knight (2012). "Preferences for genetic testing to identify hereditary colorectal cancer: perspectives of high-risk patients, community members, and clinicians." J Cancer Educ 27(1): 112-119. http://www.ncbi.nlm.nih.gov/pubmed/22131063
  31. Ponce, N. A., J. Tsui, S. J. Knight, A. Afable-Munsuz, U. Ladabaum, R. A. Hiatt and J. S. Haas (2012). "Disparities in cancer screening in individuals with a family history of breast or colorectal cancer." Cancer 118(6): 1656-1663. PMCID: 3262934. http://www.ncbi.nlm.nih.gov/pubmed/22009719
  32. Ladabaum, U. and J. M. Ford (2012). "Lynch syndrome in patients with colorectal cancer: finding the needle in the haystack." JAMA 308(15): 1581-1583. http://www.ncbi.nlm.nih.gov/pubmed/23073955
  33. Kelley, R. K., C. Atreya, A. P. Venook and P. G. Febbo (2012). "Predictive biomarkers in advance of a companion drug: ahead of their time?" J Natl Compr Canc Netw 10(3): 303-309. http://www.ncbi.nlm.nih.gov/pubmed/22393192
  34. Beattie, M. S., G. Wang and K. A. Phillips (2012). "Differences in US healthcare coverage policies in BRCA testing and potential implications." Personalized Medicine. 9(1): 5-8. http://www.futuremedicine.com/doi/full/10.2217/pme.11.85
  35. Wang, G., M. S. Beattie, N. A. Ponce and K. A. Phillips (2011). "Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling." Genet Med 13(12): 1045-1050. http://www.ncbi.nlm.nih.gov/pubmed/21844812
  36. Trosman, J. R., S. L. Van Bebber and K. A. Phillips (2011). "Health technology assessment and private payers's coverage of personalized medicine." Am J Manag Care 17 Suppl 5 Developing: SP53-60. http://www.ncbi.nlm.nih.gov/pubmed/21711078
  37. Trosman, J. R., S. L. Van Bebber and K. A. Phillips (2011). "Health technology assessment and private payers' coverage of personalized medicine." J Oncol Pract 7(3 Suppl): 18s-24s. PMCID: 3092460. http://www.ncbi.nlm.nih.gov/pubmed/21886515
  38. Pletcher, M. J. and M. Pignone (2011). "Evaluating the clinical utility of a biomarker: a review of methods for estimating health impact." Circulation 123(10): 1116-1124. PMCID: 3138723. http://www.ncbi.nlm.nih.gov/pubmed/21403122
  39. Odierna, D. H., A. Afable-Munsuz, O. Ikediobi, M. Beattie, S. Knight, M. Ko, A. Wilson and N. A. Ponce (2011). "Early developments in gene-expression profiling of breast tumors: potential for increasing black-white patient disparities in breast cancer outcomes?" Per Med 8(6): 669-679. PMCID: 3242007. http://www.ncbi.nlm.nih.gov/pubmed/22190978
  40. Lorizio, W., H. Rugo, M. S. Beattie, S. Tchu, T. Melese, M. Melisko, A. H. Wu, H. J. Lawrence, M. Nikoloff and E. Ziv (2011). "Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment." Genome Med 3(10): 64. PMCID: 3239226. http://www.ncbi.nlm.nih.gov/pubmed/21970596
  41. Liang, S. Y., K. A. Phillips, G. Wang, C. Keohane, J. Armstrong, W. M. Morris and J. S. Haas (2011). "Tradeoffs of using administrative claims and medical records to identify the use of personalized medicine for patients with breast cancer." Med Care 49(6): e1-8. PMCID: 3383782. http://www.ncbi.nlm.nih.gov/pubmed/21422962
  42. Ladabaum, U., G. Wang, J. Terdiman, A. Blanco, M. Kuppermann, C. R. Boland, J. Ford, E. Elkin and K. A. Phillips (2011). "Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis." Ann Intern Med 155(2): 69-79. PMCID: 3793257. http://www.ncbi.nlm.nih.gov/pubmed/21768580
  43. Kelley, R. K., G. Wang and A. P. Venook (2011). "Biomarker use in colorectal cancer therapy." J Natl Compr Canc Netw 9(11): 1293-1302. PMCID: 3696980. http://www.ncbi.nlm.nih.gov/pubmed/22056657
  44. Kelley, R. K. and A. P. Venook (2011). "Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?" Clin Colorectal Cancer 10(2): 73-80. PMCID: 3561586. http://www.ncbi.nlm.nih.gov/pubmed/21859557
  45. Kelley, R. K., S. L. Van Bebber, K. A. Phillips and A. P. Venook (2011). "Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer." J Natl Compr Canc Netw 9(1): 13-25. PMCID: 3695822. http://www.ncbi.nlm.nih.gov/pubmed/21233242
  46. Johnson, F. R., A. F. Mohamed, S. Ozdemir, D. A. Marshall and K. A. Phillips (2011). "How does cost matter in health-care discrete-choice experiments?" Health Econ 20(3): 323-330. PMCID: 3918954. http://www.ncbi.nlm.nih.gov/pubmed/20217834
  47. Haas, J. S., K. A. Phillips, S. Y. Liang, M. J. Hassett, C. Keohane, E. B. Elkin, J. Armstrong and M. Toscano (2011). "Genomic testing and therapies for breast cancer in clinical practice." Am J Manag Care 17(5 Spec No): e174-181. http://www.ncbi.nlm.nih.gov/pubmed/21711068
  48. Haas, J. S., K. A. Phillips, S. Y. Liang, M. J. Hassett, C. Keohane, E. B. Elkin, J. Armstrong and M. Toscano (2011). "Genomic testing and therapies for breast cancer in clinical practice." J Oncol Pract 7(3 Suppl): e1s-7s. PMCID: 3092459. http://www.ncbi.nlm.nih.gov/pubmed/21886507
  49. Haas, J. S., S. Y. Liang, M. J. Hassett, S. Shiboski, E. B. Elkin and K. A. Phillips (2011). "Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care." Breast Cancer Res Treat 130(2): 619-626. PMCID: 3590013. http://www.ncbi.nlm.nih.gov/pubmed/21681446
  50. Ferrusi, I. L., N. B. Leighl, N. A. Kulin and D. A. Marshall (2011). "Do economic evaluations of targeted therapy provide support for decision makers?" Am J Manag Care 17 Suppl 5 Developing: SP61-70. PMCID: 3918963. http://www.ncbi.nlm.nih.gov/pubmed/21711079
  51. Ferrusi, I. L., N. B. Leighl, N. A. Kulin and D. A. Marshall (2011). "Do economic evaluations of targeted therapy provide support for decision makers?" J Oncol Pract 7(3 Suppl): 36s-45s. PMCID: 3092467. http://www.ncbi.nlm.nih.gov/pubmed/21886518
  52. Ferrusi, I. L., N. B. Leighl, N. A. Kulin and D. A. Marshall (2011). "Do economic evaluations of targeted therapy provide support for decision makers?" J Oncol Pract 7(3 Suppl): 36s-45s. PMCID: 3092467. http://www.ncbi.nlm.nih.gov/pubmed/21886518
  53. Elkin, E. B., D. A. Marshall, N. A. Kulin, I. L. Ferrusi, M. J. Hassett, U. Ladabaum and K. A. Phillips (2011). "Economic evaluation of targeted cancer interventions: critical review and recommendations." Genet Med 13(10): 853-860. PMCID: 3774033. http://www.ncbi.nlm.nih.gov/pubmed/21637102
  54. Arar, N., S. J. Knight, S. M. Modell and A. M. Issa (2011). "The Genome-based Knowledge Management in Cycles model: a complex adaptive systems framework for implementation of genomic applications." Personalized Medicine. 8(2): 191-205. http://www.futuremedicine.com/doi/full/10.2217/pme.11.5
  55. Wang, G., R. K. Kelley and Gappnet (2010). "KRAS mutational analysis for colorectal cancer. Application: pharmacogenomic." PLoS Curr 2. PMCID: 2940138. http://www.ncbi.nlm.nih.gov/pubmed/20877448
  56. Van Bebber, S. L., J. R. Trosman, S. Y. Liang, G. Wang, D. A. Marshall, S. Knight and K. A. Phillips (2010). "Capacity building for assessing new technologies: approaches to examining personalized medicine in practice." Per Med 7(4): 427-439. PMCID: 3157083. http://www.ncbi.nlm.nih.gov/pubmed/21857867
  57. Trosman, J. R., S. L. Van Bebber and K. A. Phillips (2010). "Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay." J Oncol Pract 6(5): 238-242. PMCID: 2936466. http://www.ncbi.nlm.nih.gov/pubmed/21197187
  58. Marshall, D., S. E. McGregor and G. Currie (2010). "Measuring Preferences for Colorectal Cancer Screening: What are the Implications for Moving Forward?" Patient 3(2): 79-89. http://www.ncbi.nlm.nih.gov/pubmed/22273359
  59. Ladabaum, U., A. Ferrandez and A. Lanas (2010). "Cost-effectiveness of colorectal cancer screening in high-risk Spanish patients: use of a validated model to inform public policy." Cancer Epidemiol Biomarkers Prev 19(11): 2765-2776. PMCID: 3159034. http://www.ncbi.nlm.nih.gov/pubmed/20810603
  60. Kelley, R. K. and A. P. Venook (2010). "Nonadherence to imatinib during an economic downturn." N Engl J Med 363(6): 596-598. http://www.ncbi.nlm.nih.gov/pubmed/20818898
  61. Kelley, R. K. (2010). "What clinicians need to know about molecular markers in solid tumors. MedscapeCME Oncology. ." Retrieved 1/12/2015, 2015, from http://www.medscape.org/viewarticle/725989.
  62. Johnson, F. R., S. Ozdemir and K. A. Phillips (2010). "Effects of simplifying choice tasks on estimates of taste heterogeneity in stated-choice surveys." Soc Sci Med 70(2): 183-190. PMCID: 3152257. http://www.ncbi.nlm.nih.gov/pubmed/19880234
  63. Elkin, E. B. and P. B. Bach (2010). "Cancer's next frontier: addressing high and increasing costs." JAMA 303(11): 1086-1087. PMCID: 3647336. http://www.ncbi.nlm.nih.gov/pubmed/20233828
  64. Cheung, E. L., A. D. Olson, T. M. Yu, P. Z. Han and M. S. Beattie (2010). "Communication of BRCA results and family testing in 1,103 high-risk women." Cancer Epidemiol Biomarkers Prev 19(9): 2211-2219. PMCID: 3207738. http://www.ncbi.nlm.nih.gov/pubmed/20699375
  65. Bowen, D. J., J. Harris, C. M. Jorgensen, M. F. Myers and A. Kuniyuki (2010). "Socioeconomic influences on the effects of a genetic testing direct-to-consumer marketing campaign." Public Health Genomics 13(3): 131-142. http://www.ncbi.nlm.nih.gov/pubmed/19641293
  66. Wideroff, L., K. A. Phillips, G. Randhawa, A. Ambs, K. Armstrong, C. L. Bennett, M. L. Brown, M. S. Donaldson, M. Follen, S. J. Goldie, R. A. Hiatt, M. J. Khoury, G. Lewis, H. L. McLeod, M. Piper, I. Powell, D. Schrag, K. A. Schulman and J. Scott (2009). "A health services research agenda for cellular, molecular and genomic technologies in cancer care." Public Health Genomics 12(4): 233-244. PMCID: 2844634. http://www.ncbi.nlm.nih.gov/pubmed/19367091
  67. Shaukat, A., M. Parekh, J. Lipscomb and U. Ladabaum (2009). "Can calcium chemoprevention of adenoma recurrence substitute or serve as an adjunct for colonoscopic surveillance?" Int J Technol Assess Health Care 25(2): 222-231. PMCID: 2972652. http://www.ncbi.nlm.nih.gov/pubmed/19331713
  68. Phillips, K. A., D. A. Marshall, J. S. Haas, E. B. Elkin, S. Y. Liang, M. J. Hassett, I. Ferrusi, J. E. Brock and S. L. Van Bebber (2009). "Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients." Cancer 115(22): 5166-5174. PMCID: 2783254. http://www.ncbi.nlm.nih.gov/pubmed/19753618
  69. Marshall, D. A., F. R. Johnson, N. A. Kulin, S. Ozdemir, J. M. Walsh, J. K. Marshall, S. Van Bebber and K. A. Phillips (2009). "How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated-choice survey." Health Econ 18(12): 1420-1439. PMCID: 3964796. http://www.ncbi.nlm.nih.gov/pubmed/19191268
  70. Marshall, D. A. and M. Hux (2009). "Design and analysis issues for economic analysis alongside clinical trials." Med Care 47(7 Suppl 1): S14-20. http://www.ncbi.nlm.nih.gov/pubmed/19536012
  71. Liang, S. Y., J. S. Haas and K. A. Phillips (2009). "Medicare formulary coverage for top-selling biologics." Nat Biotechnol 27(12): 1082-1084. PMCID: 2845541. http://www.ncbi.nlm.nih.gov/pubmed/20010576
  72. Ikediobi, O. N., J. Shin, R. L. Nussbaum, K. A. Phillips, J. M. Walsh, U. Ladabaum and D. Marshall (2009). "Addressing the challenges of the clinical application of pharmacogenetic testing." Clin Pharmacol Ther 86(1): 28-31. PMCID: 2910521. http://www.ncbi.nlm.nih.gov/pubmed/19536122
  73. Hay, J., J. N. Harris, E. A. Waters, M. F. Clayton, L. Ellington, A. D. Abernethy and H. Prayor-Patterson (2009). "Personal communication in primary and secondary cancer prevention: evolving discussions, emerging challenges." J Health Commun 14 Suppl 1: 18-29. http://www.ncbi.nlm.nih.gov/pubmed/19449265
  74. Harris, J. N., D. J. Bowen, A. Kuniyuki, L. McIntosh, L. M. FitzGerald, E. A. Ostrander and J. L. Stanford (2009). "Interest in genetic testing among affected men from hereditary prostate cancer families and their unaffected male relatives." Genet Med 11(5): 344-355. PMCID: 2683189. http://www.ncbi.nlm.nih.gov/pubmed/19346959
  75. Harris, J., D. J. Bowen, H. Badr, P. Hannon, J. Hay and K. Regan Sterba (2009). "Family communication during the cancer experience." J Health Commun 14 Suppl 1: 76-84. http://www.ncbi.nlm.nih.gov/pubmed/19449271
  76. Ferrusi, I. L., D. A. Marshall, N. A. Kulin, N. B. Leighl and K. A. Phillips (2009). "Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses." Per Med 6(2): 193-215. PMCID: 2910630. http://www.ncbi.nlm.nih.gov/pubmed/20668661
  77. Afable-Munsuz, A., S. Y. Liang, N. A. Ponce and J. M. Walsh (2009). "Acculturation and colorectal cancer screening among older Latino adults: differential associations by national origin." J Gen Intern Med 24(8): 963-970. PMCID: 2710471. http://www.ncbi.nlm.nih.gov/pubmed/19472016
  78. Phillips, K. A., S. Y. Liang and S. Van Bebber (2008). "Challenges to the translation of genomic information into clinical practice and health policy: Utilization, preferences and economic value." Curr Opin Mol Ther 10(3): 260-266. PMCID: 2910510. http://www.ncbi.nlm.nih.gov/pubmed/18535933
  79. Phillips, K. A. (2008). "Closing the evidence gap in the use of emerging testing technologies in clinical practice." JAMA 300(21): 2542-2544. PMCID: 2910511. http://www.ncbi.nlm.nih.gov/pubmed/19050197
  80. Payne, K., W. G. Newman, D. Gurwitz, D. Ibarreta and K. A. Phillips (2008). "TPMT testing in azathioprine: a ‘cost-effective use of healthcare resources’?" Personalized Medicine 6(1): 103-113. http://www.futuremedicine.com/doi/full/10.2217/17410541.6.1.103
  81. Parekh, M., A. M. Fendrick and U. Ladabaum (2008). "As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia." Aliment Pharmacol Ther 27(8): 697-712. PMCID: 3170173. http://www.ncbi.nlm.nih.gov/pubmed/18248653